5-溴-2-氯吡啶 N-氧化物 | 889865-43-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-2-氯吡啶 N-氧化物
• 中文别名: 5-溴-2-氯吡啶-N-氧化物；5-溴-2-氯吡啶N-氧化物
• 英文名称: 5-bromo-2-chloropyridine 1-oxide
• 英文别名: 5-bromo-2-chloro-1-oxidopyridin-1-ium
• CAS: 889865-43-4
• 化学式: C₅H₃BrClNO
• 分子量: 208.442
• InChiKey: ZNOXDBXBFJQERJ-UHFFFAOYSA-N

物化性质

• 熔点：
  115-119 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R22,R37/38,R41
• WGK Germany：
  3
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H315,H318,H335
• 危险性防范说明：
  P261,P280,P305 + P351 + P338
• 海关编码：
  2933399090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 5-Bromo-2-chloropyridine N-oxide
CAS-No. : 889865-43-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Serious eye damage (Category 1)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to respiratory system and skin. Risk of serious damage to eyes.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R37/38 Irritating to respiratory system and skin.
R41 Risk of serious damage to eyes.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C5H3BrClNO
Molecular Weight : 208,44 g/mol
Component Concentration
5-Bromo-2-chloropyridine N-oxide
CAS-No. 889865-43-4 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 115 - 119 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,896
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. The
preceding data, or interpretation of data, was determined using Quantitative Structure Activity Relationship
(QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes eye burns.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-氯吡啶 N-氧化物 在 (4,4′-di-tert-butyl-2,2′-bipyridine)bis[(2-pyridinyl)phenyl]iridium(III) hexafluorophosphate 、 2,6-二甲基-1,4-二氢吡啶-3,5-二甲酸二叔丁酯 作用下， 以 乙腈 为溶剂， 反应 0.33h， 以92%的产率得到5-溴-2-氯吡啶
  参考文献：
  名称：

  使用Hantzsch酯作为轻度还原剂对N-杂环N-氧化物进行高度化学选择性脱氧

  摘要：

  在此，我们公开了适用于各种官能化的N-杂环N的高度化学选择性的室温脱氧方法。通过使用Hantzsch酯作为唯一的化学计量还原剂的可见光介导的金属光氧化还原催化而生成二氧化氮。尽管无催化剂条件可行，但大多数脱氧反应仅需使用少量催化剂即可在几分钟内完成。即使在极低的催化剂负载量为0.01 mol％的情况下，该技术也可以进行多克级反应。此可扩展且操作方便的方案的范围涵盖了广泛的官能团，例如酰胺，氨基甲酸酯，酯，酮，腈基，硝基和卤素，它们可以很好地接触到相应的脱氧N-杂环产量（总共45个实例的平均产量为86.8％）。

  DOI：

  10.1021/acs.joc.0c02805
• 作为产物：
  描述：

  5-溴-2-氯吡啶 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 5-溴-2-氯吡啶 N-氧化物
  参考文献：
  名称：

  荧光偏振用于评估PCAF BRD / Tat-AcK50缔合的小分子抑制剂

  摘要：

  开发了一种荧光偏振竞争测定法，以有效筛选和评估PCAF溴结构域/ Tat-AcK50蛋白-肽相互作用的抑制剂。合成并评估了一系列吡啶1-氧化物衍生物。一些新型化合物2-（3-氨基丙基氨基）吡啶1-氧化物衍生物可能是PCAF溴结构域/ Tat-AcK50缔合的有效抑制剂。具体来说，是2-（3-氨基丙基氨基）-5-（羟甲基）吡啶一氧化盐酸盐（15）和5-（（3-氨基丙基氨基）甲基）衍生物（20）被发现是PCAF BRD口袋的有效配体。最初的初步细胞研究表明，这些小分子抑制剂通过靶向宿主细胞蛋白PCAF BRD来阻断HIV复制，从而具有较低的细胞毒性，并且是抗HIV / AIDS治疗策略的潜在先导。

  DOI：

  10.1002/cmdc.201300499

文献信息

• Homogenous suspension of immunopotentiating compounds and uses thereof
  申请人：Skibinski David

  公开号：US09408907B2

  公开（公告）日：2016-08-09

  The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

  本发明通常涉及能够刺激或调节受需要者免疫反应的小分子免疫增强剂（SMIPs）的均匀悬浮液。这些均匀悬浮液可以与各种抗原或佐剂结合在一起用于疫苗治疗。
• [EN] COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS<br/>[FR] COMPOSÉS ET COMPOSITIONS SERVANT DE MODULATEURS DE L'ACTIVITÉ DES TLR
  申请人：IRM LLC

  公开号：WO2009111337A1

  公开（公告）日：2009-09-11

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.

  该发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物来治疗或预防与Toll样受体相关的疾病或紊乱的方法，包括TLR7和TLR8。在一个方面，这些化合物可用作辅助剂，以增强疫苗的效果（公式I），其中：X3为N；X4为N或CR3；X5为-CR4=CR5。
• Facile Route to 2-Fluoropyridines via 2-Pyridyltrialkylammonium Salts Prepared from Pyridine <i>N</i>-Oxides and Application to ¹⁸F-Labeling
  作者：Hui Xiong、Adam T. Hoye、Kuo-Hsien Fan、Ximin Li、Jennifer Clemens、Carey L. Horchler、Nathaniel C. Lim、Giorgio Attardo

  DOI：10.1021/acs.orglett.5b01703

  日期：2015.8.7

  Among known precursors for 2-[18F]fluoropyridines, pyridyltrialkylammonium salts have shown excellent reactivity; however, their broader utility has been limited because synthetic methods for their preparation suffer from poor functional group compatibility. In this paper, we demonstrate the regioselective conversion of readily available pyridine N-oxides into 2-pyridyltrialkylammonium salts under mild

  在2- [ 18 F]氟吡啶的已知前体中，吡啶基三烷基铵盐已显示出优异的反应性。然而，它们的广泛用途受到限制，因为用于其制备的合成方法具有差的官能团相容性。在本文中，我们证明了在温和且无金属的条件下，易于获得的吡啶N-氧化物向2-吡啶基三烷基铵盐的区域选择性转化。这些可分离的中间体可作为结构多样的2-氟吡啶（包括与PET成像有关的分子）的有效前体。除了提供访问非放射性类似物，此方法已被成功地应用到18 F-标记中的放射合成[ 18 F] AV-1451（[18 F] T807），目前正在开发用于对tau成像的PET示踪剂。
• Substituted Pyridone Derivative
  申请人：Ohtake Norikazu

  公开号：US20080269287A1

  公开（公告）日：2008-10-30

  Compounds of a formula (I) [wherein, A represents formula (III-1) R3 is a hydrogen, lower alkyl et al; m is 0 or 1; R1 is a hydrogen atom, halogen atom et al, R2 is a hydrogen et al; p is 0 to 4; X is a carbon atom or nitrogen atom; and X1 to X4 is a lower alkyl et al], or pharmaceutical acceptable salts thereof. These have a potency antagonistic to binding to histamine H3 receptor, or have a potency inhibiting the constant activity of histamine H3 receptor, and are useful in the therapy of obesity, diabetes et al.

  公式（I）的化合物[其中，A代表公式（III-1），R3是氢，低碳基等; m为0或1; R1是氢原子，卤原子等，R2是氢等; p为0到4; X是碳原子或氮原子; X1到X4是低碳基等]，或其药学上可接受的盐。这些化合物具有对组胺H3受体的拮抗作用，或具有抑制组胺H3受体的恒定活性的功效，并可用于肥胖症、糖尿病等疾病的治疗。
• Substituted pyridone derivative
  申请人：MSD K.K.

  公开号：US08158652B2

  公开（公告）日：2012-04-17

  Compounds of a formula (I) [wherein, A represents formula (III-1) R3 is a hydrogen, lower alkyl et al; m is 0 or 1; R1 is a hydrogen atom, halogen atom et al, R2 is a hydrogen et al; p is 0 to 4; X is a carbon atom or nitrogen atom; and X1 to X4 is a lower alkyl et al], or pharmaceutical acceptable salts thereof. These have a potency antagonistic to binding to histamine H3 receptor, or have a potency inhibiting the constant activity of histamine H3 receptor, and are useful in the therapy of obesity, diabetes et al.

  化合物的公式为(I)[其中，A代表公式(III-1)，R3为氢，低碳基等；m为0或1；R1为氢原子，卤原子等，R2为氢等；p为0到4；X为碳原子或氮原子；X1到X4为低碳基等]，或其药学上可接受的盐。这些化合物具有对组胺H3受体结合的拮抗活性，或具有抑制组胺H3受体恒定活性的活性，并可用于肥胖症、糖尿病等疾病的治疗。